Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster
Description
Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-responders depends on therapeutic antibodies or small-molecule drugs in cases of severe disease. However, perpetual viral evolution has required continuous efficacy
